{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "EMA EPAR|DISEASES|BLOOD AND LYMPHATIC DISEASES|HEMATOLOGIC DISEASES" in comments (approximate match)
Status:
US Approved Rx
(2008)
First approved in 1999
Class:
PROTEIN
Status:
US Approved Rx
(1997)
First approved in 1997
Class:
PROTEIN
Status:
US Approved Rx
(2007)
First approved in 1992
Class:
PROTEIN
Status:
US Approved Rx
(2013)
First approved in 1990
Source:
ALPHANINE SD by GRIFOLS BIOLOGICALS LLC
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1986)
Source:
BLA103132
(1986)
Source URL:
First approved in 1986
Source:
BLA103132
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1966)
First approved in 1966
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
Nuwiq by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2015
Source:
BLA125555
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02552576: Phase 4 Interventional Completed Von Willebrand Disease
(2015)
Source URL:
First approved in 2009
Source:
BLA125251
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT03449342: Phase 4 Interventional Completed Congenital Bleeding Disorder
(2018)
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
ANDA208429
(2019)
Source URL:
First approved in 2001
Source:
GLEEVEC by NOVARTIS
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Imatinib (GLEEVEC®) is a tyrosine kinase inhibitor and antineoplastic agent that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive CML. Imatinib (GLEEVEC®) inhibits colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML patients. It is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- and SCF-mediated cellular events. In vitro, imatinib (GLEEVEC®) inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.
